KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Retained Earnings (2016 - 2025)

Inovio Pharmaceuticals' Retained Earnings history spans 16 years, with the latest figure at -$1.8 billion for Q3 2025.

  • For Q3 2025, Retained Earnings fell 291647.21% year-over-year to -$1.8 billion; the TTM value through Sep 2025 reached -$1.8 billion, down 291647.21%, while the annual FY2024 figure was -$1.7 billion, 261025.36% down from the prior year.
  • Retained Earnings for Q3 2025 was -$1.8 billion at Inovio Pharmaceuticals, down from -$661742.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at -$257932.0 in Q3 2021 and bottomed at -$1.8 billion in Q3 2025.
  • The 5-year median for Retained Earnings is -$1.0 billion (2021), against an average of -$856.9 million.
  • The largest annual shift saw Retained Earnings skyrocketed 99.97% in 2021 before it plummeted 291647.21% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$282236.0 in 2021, then plummeted by 147.57% to -$698741.0 in 2022, then increased by 5.17% to -$662601.0 in 2023, then tumbled by 261025.36% to -$1.7 billion in 2024, then decreased by 5.13% to -$1.8 billion in 2025.
  • Per Business Quant, the three most recent readings for INO's Retained Earnings are -$1.8 billion (Q3 2025), -$661742.0 (Q2 2025), and -$1.7 billion (Q1 2025).